Crucell Awarded Contracts of Over $230 Million for Quinvaxem and Hepavax-Gene Vaccines

04-Dec-2006 - Crucell N.V. announced that it has been awarded contracts totaling over US $230 million for its Quinvaxem(TM) and Hepavax-Gene® paediatric vaccines by supranational organizations. The contracts cover the next three years until 2009, with the awarded amount growing over those three years. ...

Large Scale Biology Corporation Announces the Issuance of Thirteen New U.S. Patents and Several New Allowances

22-Nov-2006 - Large Scale Biology Corporation (LSBC) announced that the U.S. Patent and Trademark Office issued significant new patents covering all major areas of Company activity. Within the last 12 months, thirteen (13) new patents were issued to LSBC in the areas of gene expression, bioprocessing, ...

Organon BioSciences appoints Joost Helsen as General Manager of Nobilon

10-Nov-2006 - Joost Helsen has been appointed General Manager of Nobilon, the human vaccines business of Organon BioSciences. Nobilon is a key strategic initiative, founded in 2002, that bridges Intervet's expertise in vaccine development with Organon's ability to register and market human health care ...

Generex Biotechnology to begin human trial of avian influenza vaccine

08-Nov-2006 - Generex Biotechnology Corporation announced that it has entered into an agreement with the Lebanese-Canadian Hospital in Beirut, Lebanon to conduct a human clinical trial of the Antigen Express synthetic avian influenza vaccine, representing the first studies to be conducted in man, according to ...

Geron licenses antigen targeting patents for cancer research vaccine program from Immunomic Therapeutics

07-Nov-2006 - Geron Corporation and Immunomic Therapeutics Inc. (ITI) announced a patent license agreement under which Geron will receive exclusive rights to the LAMP antigen targeting sequence for use in cancer vaccines. Geron's therapeutic cancer vaccine, GRNVAC1, triggers an immune response against the ...

Pfizer agreement to acquire Powdermed Ltd.

Acquisition Marks Strategic Entry Into DNA-Based Vaccines

10-Oct-2006 - Pfizer Inc announced has entered into an agreement to acquire PowderMed Ltd., a privately held U.K. company specializing in the emerging science of DNA-based vaccines. PowderMed has developed a unique and proprietary technology to deliver DNA directly to the cells of the body's immune system and ...

Acambis sells Berna Products to Crucell for $16.5m

05-Oct-2006 - Acambis plc announces the sale of its Berna Products Corporation business to Crucell NV . Berna Products is no longer a strategic asset for Acambis following the termination of the ARILVAX licensing agreement, which was announced on 12 September. The sale agreement and consequential termination ...

Intercell enters into strategic partnership with Wyeth for the use of its IC31TM adjuvant in various infectious disease vaccines

14-Sep-2006 - Intercell AG announced that it has closed a worldwide nonexclusive agreement under which Wyeth has the right to use Intercell's fully synthetic novel adjuvant IC31TM in various selected infectious disease vaccine programs. Under the agreement, Intercell may be entitled to receive up to USD 77 ...

Collaboration of Intercell with PATH for the development of Intercell's Streptococcus pneumoniae vaccine

08-Sep-2006 - Intercell and PATH, a USbased nonprofit organization dedicated to finding solutions for global health issues announced an agreement to advance the development of Intercell's Streptococcus pneumoniae vaccine. Intercell will receive a total of USD 7.3 m during the first stage of the collaboration, ...

New Study Unveils Structure of Key Component of Antibiotic Resistant Bacteria

Findings Could Offer Help in Fighting Resistant Strains of Gonorrhea

07-Sep-2006 - Working in close collaboration with other researchers, scientists from The Scripps Research Institute have uncovered for the first time the structural chemistry behind the "astonishing multi-functionality" of the bacterial GC (for gonococcal) Type IV pilus filament, which plays an essential role ...